| Dr James Philip Pursglove, DO | |
|
300 W 27th St, Lumberton, NC 28358-3075 | |
| (910) 735-8783 | |
| (910) 671-5392 |
| Full Name | Dr James Philip Pursglove |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 6 Years |
| Location | 300 W 27th St, Lumberton, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831688928 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 2021-02386 (North Carolina) | Secondary |
| 207P00000X | Emergency Medicine | OP61272916 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Capital Medical Center | Olympia, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Olympia Emergency Care Physicians Pllc | 2769862036 | 29 |
News Archive
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2011.
› Verified 4 days ago
| Entity Name | Sunnyside Emergency Group A Professional Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033529367 PECOS PAC ID: 0941424451 Enrollment ID: O20140623002600 |
News Archive
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2011.
› Verified 4 days ago
| Entity Name | Western Washington Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801352505 PECOS PAC ID: 0749514735 Enrollment ID: O20190625002379 |
News Archive
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2011.
› Verified 4 days ago
| Entity Name | Sound Physicians Emergency Medicine Of Washington Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629532064 PECOS PAC ID: 7315279007 Enrollment ID: O20191030000855 |
News Archive
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2011.
› Verified 4 days ago
| Entity Name | Olympia Emergency Care Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396498671 PECOS PAC ID: 2769862036 Enrollment ID: O20220704000366 |
News Archive
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2011.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Philip Pursglove, DO 300 W 27th St, Lumberton, NC 28358-3075 Ph: (910) 735-8783 | Dr James Philip Pursglove, DO 300 W 27th St, Lumberton, NC 28358-3075 Ph: (910) 735-8783 |
News Archive
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Hillenbrand, Inc. has entered into a definitive agreement to acquire privately held Coperion Capital, a portfolio company of Deutsche Beteiligungs AG, for an estimated purchase price of €408 million ($530 million at current exchange rates), which includes the assumption of an estimated €76 million of net debt and €100 million pension liability.
Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2011.
› Verified 4 days ago
Michael Bruss, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 300 W 27th St, Lumberton, NC 28358 Phone: 910-671-5000 | |
Erin Broderick, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 300 West 27th Street, Southeastern Health, Lumberton, NC 28359 Phone: 910-272-1478 Fax: 910-671-5392 | |
Dr. Bruce S. Whitman, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 W 27th St, Lumberton, NC 28358 Phone: 910-671-5000 | |
Dr. Karl Michael Duerr, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 W 27th St, Lumberton, NC 28358 Phone: 910-671-5000 | |
Jenna Santiago-wickey, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 W 27th St, Lumberton, NC 28358 Phone: 910-272-1478 Fax: 910-671-5392 | |
Dr. Aleksandr Pevtsov, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 W 27th St, Lumberton, NC 28358 Phone: 910-735-8783 | |
Douglas Nederostek, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 W 27th St, Lumberton, NC 28358 Phone: 910-671-5000 |